PRESS RELEASE published on 08/13/2026 at 16:52, 28 days 19 hours ago Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Targets Disability Drivers Beyond Relapse Rates in Multiple Sclerosis Austin, Texas, August 13th, 2026, FinanceWire
PRESS RELEASE published on 08/13/2026 at 16:52, 28 days 19 hours ago BOXABL (NASDAQ: BXBL) Launches Partnership Initiative to Advance Affordable Housing at Scale Austin, Texas, United States, August 13th, 2026, FinanceWire
PRESS RELEASE published on 08/13/2026 at 16:52, 28 days 19 hours ago BOXABL (NASDAQ: BXBL) Launches Partnership Initiative to Advance Affordable Housing at Scale Austin, Texas, August 13th, 2026, FinanceWire
PRESS RELEASE published on 08/13/2026 at 16:50, 28 days 19 hours ago G6 Hospitality Strengthens Franchise Engagement Through Nationwide Town Halls Dallas, Texas, August 13th, 2026, FinanceWire
PRESS RELEASE published on 08/13/2026 at 16:47, 28 days 19 hours ago Beneflo Expands Employee Benefits Platform Across the Baltic Region and Beyond Riga, Latvia, August 13th, 2026, FinanceWire
PRESS RELEASE published on 08/13/2026 at 16:31, 28 days 20 hours ago ClickHouse and Hud Connect the Dots Between AI Code, Production Data and Engineering Decisions New York, USA, August 13th, 2026, FinanceWire
PRESS RELEASE published on 08/13/2026 at 16:15, 28 days 20 hours ago Amanahkredit Expands Accessible Short-Term Loan Solutions for Students and Housewives Across Malaysia KUALA LUMPUR, Malaysia, August 13th, 2026, FinanceWire
PRESS RELEASE published on 08/13/2026 at 15:52, 28 days 20 hours ago Form 8.3 - The Vanguard Group, Inc.: Prologis, Inc. The Vanguard Group, Inc. discloses a 13.49% stake in Prologis, Inc. with relevant securities. Additional disclosures involve SEGRO plc. Transactions include purchasing and selling USD 0.01 common shares Transactions Relevant Securities Disclosure The Vanguard Group Prologis Inc.
PRESS RELEASE published on 08/13/2026 at 15:51, 28 days 20 hours ago Form 8.3 - The Vanguard Group, Inc.: DNO ASA The Vanguard Group, Inc. discloses a 3.49% stake in DNO ASA. Form 8.3 filing on 13-Aug-2026 Form 8.3 Vanguard Group Financial Disclosure Stake Disclosure DNO ASA
PRESS RELEASE published on 08/13/2026 at 15:51, 28 days 20 hours ago Form 8.3 - The Vanguard Group, Inc.: JTC plc The Vanguard Group, Inc. discloses 4.94% interest in JTC plc through relevant securities. Details of positions and dealings provided Securities Vanguard Group Financial Disclosure Dealing JTC Plc
Published on 09/11/2026 at 04:00, 8 hours 40 minutes ago Torq Announces Debt Settlement and Corporate Update
Published on 09/10/2026 at 22:25, 14 hours 15 minutes ago Pathfinder Ventures Announces Appointment of Mickey Perret as Chief Executive Officer
Published on 09/10/2026 at 15:20, 21 hours 20 minutes ago MicroVision to Preview Next-Generation Lidar-Based Perception Platform at IAA Transportation 2026
Published on 09/10/2026 at 15:00, 21 hours 40 minutes ago All Randomized Pediatric Patients to Continue in the Single-Blind Extension Phase of Jaguar Health's Pivotal Clinical Trial of Crofelemer for Microvillus Inclusion Disease (MVID) with Intestinal Failure (IF)
Published on 09/11/2026 at 11:43, 57 minutes ago Skyborn reaches Financial Close on the Gennaker offshore wind farm project
Published on 09/11/2026 at 11:35, 1 hour 5 minutes ago EQS-Adhoc: Correction of a release from 10/09/2026, 19:35 CET/CEST - United Internet AG: Group subsidiaries 1&1 AG and IONOS Group SE launch transformation programs
Published on 09/11/2026 at 11:30, 1 hour 10 minutes ago Galimedix Therapeutics to present functional feasibility data from Phase 2 eDREAM study in geographic atrophy at 26th EURETINA Congress
Published on 09/11/2026 at 10:15, 2 hours 25 minutes ago TCMA Receives Two National Awards, Highlighting Thailand’s Cement Industry Progress Towards Net Zero 2050
Published on 09/11/2026 at 07:00, 5 hours 40 minutes ago Transparantiekennisgeving van Baltisse Groep
Published on 09/11/2026 at 07:00, 5 hours 40 minutes ago BIOPHYTIS ANNOUNCES COMPLETION OF €5.3 MILLION CAPITAL INCREASE TO FUND ITS PHASE 2 TRIAL IN OBESITY
Published on 09/11/2026 at 07:00, 5 hours 40 minutes ago BIOPHYTIS ANNONCE LA RÉALISATION D’UNE AUGMENTATION DE CAPITAL DE 5,3 MILLIONS D’EUROS DESTINÉE À FINANCER SON ESSAI DE PHASE 2 DANS L’OBÉSITÉ
Published on 09/10/2026 at 19:30, 17 hours 10 minutes ago Availability of the 2026 Interim Financial Report
![Logo of [UNKNOWN]](https://logos.symex.be/img/.jpg)
